Not Yet RecruitingNot Applicable

Immersive Virtual Reality for Older Adults in Long-Term Care Settings

36 participantsStarted 2026-06-15

Plain-language summary

The goal of this clinical trial is to learn if an immersive virtual reality mindfulness meditation program is feasible and acceptable for older adults living in long-term care settings in Quebec who have mild to moderate neurocognitive disorder. It will also learn about the safety and potential effects of the program on well-being. The main questions it aims to answer are: * Is the virtual reality mindfulness meditation program feasible and acceptable for residents and staff in long-term care settings? * Does the adapted version of the program show potential benefits for well-being, including depression, anxiety, quality of life, mindfulness, pain, and loneliness? * What practical challenges, user experiences, and side effects, such as cybersickness, occur during the program? Researchers will compare the original Toujours Dimanche virtual reality mindfulness meditation program, an adapted version of Toujours Dimanche designed for older adults with mild to moderate neurocognitive disorder, and standard care alone to see if the adapted program is feasible, acceptable, and potentially helpful. Participants will: * Take part in up to 8 virtual reality mindfulness meditation sessions over 4 weeks, if assigned to a virtual reality group * Complete questionnaires before and after the 4-week study period * Share feedback about their experience, when possible * Be observed by staff or research team members to document feasibility, acceptability, user experience, and safety

Who can participate

Age range

60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: For resident participants: * Resident of a participating long-term care facility, seniors' home, or alternative seniors' home in the Chaudière-Appalaches or Capitale-Nationale regions of Quebec * Aged 60 years or older * Able to understand French or English * Able to provide informed consent or assent, or have consent provided by a legally authorized representative or person authorized to consent * Mild to moderate cognitive impairment or neurocognitive disorder * Normal or corrected vision and hearing For staff participants: * Regularly works with at least one resident participating in Phase 3 * Has completed the revised virtual reality training provided by Super Splendide and/or Martine Bordeleau Exclusion Criteria: For resident participants: * Recurrent migraines * Epilepsy * Traumatic brain injury during the past year * Glaucoma or recovery from eye surgery * Diagnosed uncontrolled epilepsy * Diagnosed severe vertigo * Severe hearing impairment without a corrective hearing device * Significant visual impairment that would prevent use of a virtual reality headset * Motion sickness that would prevent use of a virtual reality headset * Any health condition that restricts movement or prevents safe participation, such as a significant reduction in neck or upper-limb range of motion

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial is described as 'not yet recruiting' — do you know when it might open for enrollment, and would it make sense for us to stay in touch with the research team in the meantime?
2Since this study is in a feasibility phase rather than a later phase, it's primarily checking whether the virtual reality approach is practical and safe to run — not yet proving it works — so how does that affect whether it might be a good fit compared to established treatments for depression or anxiety that are already available?
3The trial is specifically designed for older adults in long-term care settings — does my current living situation and level of cognitive impairment match what they're likely looking for in participants?
4The study measures changes in both depression and anxiety symptoms using immersive virtual reality — given my specific symptoms and history, do you think this kind of non-drug approach is worth exploring alongside or instead of what I'm currently doing?
5The trial is also tracking things like how well participants stick with the sessions and whether the VR headsets are safe and comfortable to use — are there any concerns about my health or physical condition, like balance issues or vision problems, that might make wearing VR equipment difficult or risky for me?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Recruitment, Retention, Adherence, Blinding, and Safety Feasibility Indicators

Timeframe: Up to 4 weeks

Acceptability of the Intervention

Timeframe: At 4 weeks

Change in Depression Symptoms

Timeframe: Baseline and 4 weeks

Change in Anxiety Symptoms

Timeframe: Baseline and 4 weeks

Trial details

NCT IDNCT07658287

SponsorLaval University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06-15

Contact for this trial

Martine Bordeleau, PhD

581-490-2626 martine.bordeleau@outlook.com

View on ClinicalTrials.gov More Cognitive Impairment trials